Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy of fixed-duration venetoclax-based regimens as first-line in chronic lymphocytic leukemia: A systematic review and meta-analysis of clinical trials

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAbdulrahman Al‐MashdaliWAWajeeha AimanRMRowan Mesilhy

Discussion

Loading...

Member takes

Overview

Meta-analysis demonstrates improved progression-free survival in chronic lymphocytic leukemia with venetoclax regimens, suggesting viable first-line options.

Key Points

  • Venetoclax-based regimens yielded improved progression-free survival compared to chemoimmunotherapy in chronic lymphocytic leukemia patients.
  • In randomized controlled trials, venetoclax combinations showed superior efficacy metrics, with notable differences in overall response rates.
  • The analysis included multiple randomized controlled trials assessing treatment outcomes, highlighting the significance of regimen personalization.
  • Findings indicate that while neutropenia was common, venetoclax therapies may have a more favorable adverse events profile compared to traditional chemotherapy.

Cite This Study

Al‐Mashdali et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1c6https://doi.org/10.1182/blood-2025-7414
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis2025
  2. 2Real‑world effectiveness and patient-centered outcomes of fixed‑duration vs continuous first‑line therapy in chronic lymphocytic leukemia (CLL)2025
  3. 3Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025
  4. 4Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial2025 · 4 citations
  5. 5First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry2025